

TOGETHER, WE **WILL** FIND THE CURE



CROHN'S AND COLITIS FOUNDATION OF CANADA
2005-2006 REPORT

Inflammatory Bowel Disease (IBD) describes two similar yet distinct conditions: Crohn's disease and ulcerative colitis. These chronic diseases of the digestive system affect 170,000 Canadian men, women and children.

There is no known cause or cure.



Crohn's and Colitis
Foundation of Canada

Fondation canadienne des
maladies inflammatoires
de l'intestin



MISSION: FIND THE CURE

VISION

The Crohn's and Colitis Foundation of Canada (CCFC) believes that a cure will be found for Crohn's disease and ulcerative colitis. To realize this, the CCFC is committed, first and foremost, to raise increasing funds for medical research.

The CCFC also believes it is important to make all individuals with inflammatory bowel disease (IBD) aware of the Foundation, and educate these individuals, their families, health professionals and the general public about these diseases.

VALUES

In undertaking this vision, the CCFC believes:

- The greatest proportion of funds raised must be allocated to research;
- Collaboration with the medical community is imperative;
- Goals must be set and met throughout the organization;
- Participation by volunteers is crucial to our success;
- The success of the Foundation rests on the mutual respect of staff and volunteers;
- The national nature of the Foundation must be respected;
- All volunteers, members, supporters and employees have a right to contribute in an environment that asserts the personal worth and dignity of each individual.

National Board of Directors of the CCFC 2005-2006

The Foundation is governed by a volunteer National Board of Directors elected by its members. The Board oversees our operations, sets national policies and establishes goals for the Foundation.

National President

Randy Sabourin, Mississauga, ON

National Past President

Nathalie Fradet, Sainte-Therese, QC

National Treasurer

Ashraf Matta, Toronto, ON

National Secretary

Victoria Prince, Toronto, ON

National V.P. Alberta / NWT / Nunavut

Brad Zerr, St. Paul, AB

National V.P. British Columbia / Yukon

Michael Quigley, Abbotsford, BC

National V.P. Manitoba / Saskatchewan

Nancy Nagy, Winnipeg, MB

National V.P. Maritimes

Margaret Prouse, North Whiltshire, PEI

National V.P. Newfoundland / Labrador

Hilary Vavasour, St. John's, NF

National V.P. Ontario

Lisa Baillie, Wellesley, ON

National V.P. Quebec

Lori Karpman, Montreal, QC

Directors at Large

Cameron Anderson, Kitchener, ON

Kate Dalgligh, Toronto, ON

Jan Martin, Mississauga, ON

Nick Westlind, Toronto, ON

CCFC Honourary Patron

Her Excellency the Right Honourable
Michaëlle Jean C.C., C.M.M., C.O.M., C.D.
Governor General of Canada

MESSAGE FROM THE NATIONAL EXECUTIVE DIRECTOR AND NATIONAL PRESIDENT



From left to right: Michael Howorth, National Executive Director, Randy Sabourin, National President

For the 7th year in row we've exceeded our previous years' investments into IBD research.

The CCFC has also achieved another record year in fundraising. In May 2006 the M&M Meat Shops Charity BBQ Day raised an astounding \$1.8 million and the Heel 'n' Wheel-A-Thon contributed an amazing \$1.42 million. The Gala events this year were again exceptional and the contributions from regional hockey, golf tournaments and other numerous events also outpaced themselves.

Fundraising was up in all the major categories; what a great year! This providence was not delivered to us by luck or "being in the right place at the right time". Our many partners – volunteers, sponsors, donors, members and staff – worked very hard and deserve our thanks and our praise for a performance that any public company would be proud to report to their shareholders.

This result is important for three significant reasons. First and foremost it allows us to work towards our Mission of finding the cure by continuing to fund the most extensive IBD research in the world. We fund over 50 world-class researchers – a significant financial responsibility for the CCFC. This commitment is up 42 % from last year and 95% over the last 5 years.

We sponsored our third major international research conference last year, bringing the IBD research community together in an effort to continue the pressure for results. The theme of IBD 2005 was "Are we there yet?" and we were very impressed with the dedication and sense of urgency that exist amongst our research partners.

Second, another year of great results revealed that the operation, processes and dedication of the CCFC continue to be "best in class". It's no accident that our corporate sponsors are extremely happy with us and our international reputation is attracting the best doctors and researchers to work with us on our Mission to find a cure. We have attracted some of the country's best business people to serve on our Board, both now and in the past, and we continue to attract volunteers from every walk of life who contribute their time and energy in a world where leisure time is quickly disappearing.

Third but certainly not least, these results are significant because you, our CCFC partners, achieved them. The CCFC is a volunteer driven charity; we have a very high net contribution rate from money raised because so many people are willing to shoulder the work. Whether it's selling tickets for a boat cruise, being a sponsor for the Heel 'n' Wheel or flipping burgers on M&M Charity BBQ Day, our partners are the ones that make the difference and manufacture the results.

The details of our continued success are enclosed in this report, but as you're reading them keep a few things in mind. This past year was record-breaking and you, our partners, played a most important part in this success. Be very proud of your contribution and know that we plan to break all these records again in the 2006 – 2007 year. With your help we can do it; that's why we say, "Together we will find the cure."

Michael J. Howorth
National Executive Director

Randy Sabourin
National President



RESEARCH IS OUR PRIORITY

“The importance of CCFC funding on IBD research continues to be integral to the quest for answers into the mysteries of Crohn’s disease and ulcerative colitis. As we expand our knowledge and discover new insights into these diseases, researchers in Canada are grateful to the Foundation for its support. As we break ground in the basic mechanisms, epidemiology and genetics of IBD, we move closer to new treatments.”

DR. KENNETH CROITORU, CHAIR CCFC IBD RESEARCH INSTITUTE

Our mission is, “Find the Cure”. In a relentless pursuit to accomplish that mission, the CCFC is proud to fund medical research that provides insights into the cause and treatment of inflammatory bowel disease. In the past year, research investments have continued to grow and we announced thirteen new Grants in Aid of Research for a total investment of four and a quarter million dollars.

Consider this – in 1990 we were able to fund four Grants in Aid of Research. Sixteen years later, with the help of our many partners, the CCFC has increased IBD research over three fold.

Since 1997, the CCFC has invested over \$25 million in new and ongoing research and over \$40 million since the inception of the Foundation. But we are not content with that - the drive to fund more research in the future will continue, until our mission is accomplished.

Here is where we invested research monies in 2005.

2005 – 2006 RESEARCH HIGHLIGHTS

INCREASED FUNDING

For the first time, the CCFC has been able to invest over \$5 million in research grants. Because of the generous support from donors, we have been able to award funding to researchers through Grants in Aid of Research, Research Scientist Awards, Innovations in IBD Research, Student Scholarships, Post Doctoral Faculty Transition Awards and CAG/CCFC Fellowship Awards.

VISITING SCIENTIST PROGRAM

Dr. Martin Storr, a world-renowned German gastroenterologist and scientist, has arrived in Canada to spend one year working with researchers at the University of Calgary. The Visiting Scientist program is designed to foster an exchange of knowledge from around the world to enhance IBD research conducted in this country.

NATIONAL NETWORK TISSUE BANK

Initiated in 2002, the National Network Tissue Bank is an ongoing storage and distribution platform for tissue samples of patients with IBD. Samples are taken

from newly diagnosed patients and control patients, to allow comparison of the bacteria in the bowel.

CLINICAL TRIALS CONSORTIUM

The CCFC encourages the exchange of ideas and dynamic new approaches to treating the symptoms and finding the cure for IBD through a network of the best clinical trial specialists in Canada.


GEM PROJECT

The design of the Genetic, Environmental and Microbial (GEM) Project is nearing completion. This ambitious project will study unaffected first-degree relatives of people with Crohn’s Disease, following them over time.

NURTURING FUTURE SCIENTISTS

CCFC believes that the one of the keys to future success lies in the constant entry of new scientists to the field of IBD research. We have been struck by the dramatic improvement in the number of young IBD scientists in Canada, and we believe this to be a direct result of the investments made in research and personnel since the 2000 IBD conference.

CCFC RESEARCH INVESTMENTS:
LEADING TO THE CURE
1997 – 2006





VISION 2006 AND BEYOND

In 2005, the CCFC hosted an international conference, inviting scientists from around the world to participate in sessions on a wide variety of topics related to IBD. Spirited discussions and informative exchanges of information stimulated the participants, enhancing the global body of knowledge surrounding Crohn's disease and ulcerative colitis.

Following the conference, CCFC Professional Members met in small group planning sessions to brainstorm recommendations for the National Board on future programming and research priorities. Their recommendations were presented by the Organizing Committee to the Board and form the basis for the CCFC research vision in 2006 and beyond.

CCFC IBD RESEARCH INSTITUTE

Ever since it was launched in 2003, this virtual institute has been incredibly active in the development of research into IBD. Led by health professionals who volunteer their time and formidable energy, the Institute has played a key role in providing scientific advice to the CCFC's research and education programs.

EXECUTIVE COUNCIL OF THE RESEARCH INSTITUTE

The Executive Council advises the National Board of Directors of the CCFC in the areas of policy development, Foundation goals and measures for outcome evaluation of CCFC research.

In addition, the Executive Council advises the National Executive Director on the administration of the Foundation's research and education programs in his role of management and implementation of CCFC activities. The National Executive Director is an ex-officio member of the Executive Council.

With our gratitude, Dr. Kenneth Croitoru and Dr. Hillary Steinhart completed their terms as Chair and Vice-Chair respectively, in June 2006. In addition, the Chair of Liaison Activities also became vacant at the end of June when Dr. Stephen Collins' expanded responsibilities at McMaster University required that he vacate the position.

Subsequent elections returned Drs. Croitoru and Steinhart to their executive positions for another three years. Dr. Stephen Vanner was elected as Chair, Liaison Activities.

The Executive Council of the Research Institute 2005 – 2006

Chair, **Dr. Ken Croitoru**,
McMaster University

Past Chair, **Dr. Lloyd Sutherland**,
University of Calgary

Vice Chair, **Dr. Hillary Steinhart**,
University of Toronto

Chair, Research,
Dr. Karen Madsen,
University of Alberta

Chair, Clinical Consortia,
Dr. Brian Feagan,
University of Western Ontario

Chair, Communications,
Dr. Charles Bernstein,
University of Manitoba

Chair, Liaison Activities,
Dr. Stephen Collins,
McMaster University

Chair, Scientific Symposia,
Dr. Andrew Stadnyk,
Dalhousie University

Chair, Personnel Development,
Dr. Derek McKay,
McMaster University



From left to right: Dr. Kenneth Croitoru, 2003-2006 Chair of RI, Dr. Hillary Steinhart, 2003-2006 Vice-Chair of RI, Dr. Stephen Collins, 2005-2006 Chair Liaison Activities of RI



Dr. Andrew Stadnyk, Dalhousie University

NEUTROPHIL MIGRATION

Dr. Stadnyk's research focused on mechanisms which would inhibit the migration of neutrophils from the blood into the colonic lumen. The presence of neutrophils in the colonic lumen cause crypt abscesses which damage the epithelium and could possibly cause ulcers.

His research focused on the long-term goal of identifying the adhesion molecules used in the migration of neutrophils with the premise that preventing their migration would dampen inflammation.

In addition, Dr. Stadnyk and his team conducted experiments to determine what chemoattractants are responsible for recruiting neutrophils into the colonic lumen.

The advances made by Dr. Stadnyk over the past three years have strengthened his conviction that neutrophil interactions with the intestinal epithelium are important in the mechanisms of inflammation. He plans to continue his work in chemoattractants within the lab and with colitic mice with the goal of promoting effective antagonists for the treatment of IBD.

WHAT WE'VE LEARNED GRANTS IN AID OF RESEARCH 2003 – 2006

In over 30 years, the CCFC has sponsored hundreds of Grants in Aid of Research in an effort to find the cure. Research scientists must demonstrate scientific excellence and relevance to our mission in order to be awarded one of these grants.

In 2004, Grants in Aid of Research were increased to a maximum of \$150,000 per year, for one to three years. Because of the generosity of our many partners, this enriched funding has provided researchers with the additional support that allows them to concentrate on their search for solutions to the myriad of questions that surround IBD.

Canada is home to some of the world's leaders in IBD research. The CCFC is proud to be affiliated with these outstanding professionals and to be able to further their work by supporting their research. These summaries are the key findings of studies funded to 2006.



Dr. Paul Kubes, University of Calgary

T-CELL RECRUITMENT INTO THE INFLAMED LIVER

Two years ago Dr. Kubes received a CCFC grant to study how Th1 and Th2 white cells migrate to sites of inflammation and observe how these cells behave in inflamed intestinal vasculature. Using new fluorescence intravital microscopy approaches, Dr. Kubes and his team noted that both Th1 and Th2 cells use Velcro-like molecules to stop in blood vessels and then move out of the vessels.

This finding was not in keeping with scientific data at that time and challenged the previously established paradigms of thought. Since that time, three other research papers have been published which corroborate the findings of Dr. Kubes.

Primary sclerosing cholangitis, a chronic inflammatory liver disease characterized by progressive bile destruction, frequently develops as an extra-

intestinal complication of IBD. There is a growing body of evidence that the same T cells which enter and cause disease in the intestines also inappropriately infiltrate the liver causing hepatic disease. For this reason, Dr. Kubes compared and contrasted how Th1 and Th2 cells trafficked to the liver compared to the intestine. He discovered that T cells use very different molecules to gain liver access.

An unexpected and fascinating turn of events has also come about as a result of recent experiments. Dr. Kubes and his team have identified a new molecule, CD44, which is involved in getting T cells into the intestine. This observation suggests that CD44 is somehow crucial for other molecules that help T cells get into the intestine.

Dr. Derek McKay, McMaster University

THE MODULATION OF COLITIS BY TAPEWORM PARASITES

The basic premise of the research performed by Dr. McKay and his team is that tapeworm parasites, such as *Hymenolepis diminuta*, are potent activators of their host's immune system. In response to infection by a parasite, a human host typically responds with cellular events and production of inflammatory mediators that are driven by the mobilization of lymphocytes.

Dr. McKay's team studied a mouse model of the rat tapeworm to determine if this parasite could relieve colitis and if so, by what mechanism(s).

During their project, his team discovered that infection with *H. diminuta* eight to twenty-one days before exposure to a pro-colitic agent significantly reduced the development of colitis in male and female mice. In addition, when administered as a co-treatment, the tapeworm reduced colitis in the animals.

The parasitic infection was also associated with increased naturally produced interleukins (IL: essential for the body's immune response).

One in particular, IL-10, when neutralized by an anti-IL-10 antibody blocked the anti-colitic effect that accompanied tapeworm in this mouse model system.

Infection with the rat tapeworm did not increase mice sensitivity to other antigens (substances that provoke an immune response) or to anaphylaxis (sudden, severe and potentially fatal allergic reaction).

In separate analyses, Dr. McKay also found that an adult worm antigen preparation contained an interleukin-like molecule that enhanced the production of IL-10 from stimulated immune cells.

Data from on-going studies will continue to fascinate Dr. McKay and his team on the effects of the tapeworm parasite.



Dr. Nathalie Vergnolle, University of Calgary

THROMBIN RECEPTORS

During her three-year project, Dr. Vergnolle and her team studied the effects of the activation of thrombin receptors PAR₁ and PAR₄ and whether this activation generated and/or inhibited the inflammation and pain so common to inflammatory bowel disease. In addition, they investigated how PAR₁ participated in the cause, nature and development of chronic colitis.

In their studies, they determined that PAR₁ provokes inflammation through a mechanism that activates the immune system. They also discovered that blocking the PAR₁ receptor is beneficial in protecting animals from the development of experimental colitis similar to Crohn's Disease but can worsen experimental colitis in other models closer to allergic reaction.

In the last year, Dr. Vergnolle also investigated the implications of PAR₄ in the development of inflammatory bowel disease in animals. Their experiments showed that blocking PAR₄ through a pharmacological approach was beneficial in preventing the development of colitis in animals.

Dr. Vergnolle's results showed that PAR₄ and PAR₁ act differently from one another and both are potential targets for the treatment of IBD. She and her team are now looking forward to investigating the enzymes or proteases that activate these thrombin receptors and determining if they could be therapeutic targets for future treatments of IBD.





Dr. Pierre-Yves von der Weid, University of Calgary

LYMPHATIC VESSEL CONTRACTILE ACTIVITY IN INTESTINAL INFLAMMATION

Inflammatory bowel disease (IBD) is a multifactorial disorder, with the cause remaining uncertain. Swelling between tissues, dilatation and/or obstruction of lymphatic vessels are features associated with IBD, each of which can contribute to the development of symptoms.

Lymphatic vessels are important components of mesenteric and intestinal circulation. They remove fluid, proteins and lipids from the gut by increasing lymph flow via rhythmic constrictions or lymphatic pumping. Impairment of this pumping action may cause swelling, or edema.

Normally during inflammation, lymphatic pumping should increase to prevent edema. However in IBD, it is hypothesized that inflammatory mediators, which can reach lymphatic vessels, adversely affect their contractile function and lymph flow.

Dr. von der Weid's research investigated the contractile activity of lymphatic vessels during intestinal inflammation. He was interested in assessing whether this function was altered during the development of IBD and the role that inflammatory mediators (such as cyclooxygenase products) play in the dysfunction.

Their results demonstrated that in animal models, lymphatic pumping was indeed impaired compared to the control animals, with a high degree of correlation between the dysfunction and the degree of inflammation present.

It was also found that cyclooxygenase products appeared to contribute to the lymphatic dysfunction by decreasing the pumping activity of the lymph vessels.

Dr. von der Weid and his team are currently searching for the source of these products as well as the enzymes that produce them.



Dr. Karen Madsen, University of Alberta

BACTERIAL DNA AND INFLAMMATORY BOWEL DISEASE

For the last three years, Dr. Madsen has been studying bacterial DNA and its effects on IBD. From 2003 - 2006, she and her research team have been investigating the role of bacterial DNA in modulating epithelial inflammatory responses; assessing its efficacy as a therapeutic modality in models of colitis and determining the effects of exposure of the developing immune system in neonates to various types of bacterial DNA.

Over the course of this grant, she found that isolated bacterial DNA could affect the function of immune and epithelial cells by changing the way certain proteins are replicated and broken down. She also found that the introduction of probiotic bacterial DNA into mice hosts with inflammation reduced inflammation and improved the state of their disease.

Her studies found that exposure of neonates to certain bacterial DNA in combination with some, but not all, bacterial antigens resulted in an increased immune response in the gut of newborn mice for several weeks after exposure.

Finally, a series of experiments were also carried out to examine the effects of probiotic bacteria DNA in preventing gut barrier dysfunction and sepsis. While results differed when using live probiotic bacteria compared with probiotic DNA, both appeared to reduce the movement of destructive bacteria across the gut wall, thereby preventing infection.

Overall, her data indicated that both live probiotics and probiotic DNA can maintain colonic barrier and transport function in the presence of inflammation and infection. This in turn supports a potential role for probiotic bacteria and probiotic bacterial DNA in treating inflammation and preventing infection in patients with acute inflammatory bowel disease.

VOLUNTEERS – OUR HEART AND SOUL

Dedication, determination and creativity are just some of the words that come to mind when we think of our volunteers. Whether they work alone or in teams whose members number into the thousands, our amazing volunteers are the driving force behind the CCFC fundraising success.

Research needs funding to support it and our volunteers' efforts make it possible for researchers to continue their vital work. That's why we say, "Together, we will find the cure."

M&M MEAT SHOPS CHARITY BBQ DAY

Another record smashing success! This year, the M&M Meat Shops Charity BBQ Day raised an incredible \$1.8 million for IBD research. A winning combination of fantastic burgers and hot dogs; volunteer "grillers", servers and cashiers and a supportive (and hungry) public across the country made for another record-breaking day.

Thank-you M&M Meat Shops franchisees and staff for your generosity.

2006 GIFT/CCFC SUPERGALA

Once again the CCFC is grateful to the Grocery Industry Foundation....Together (GIFT) for partnering with us to stage the 2006 GIFT/CCFC SuperGala. This past year, the event raised over \$1.3 million for the CCFC.

And a special thank you to the organizing committee: Co-chairs Simon Zucker (Simon Zucker & Associates), Don Crombie (Crombie Kennedy Nasmark Inc.); Committee members Michael Burrows (E.D. Smith & Sons Ltd.); David Houlden, Dan Shapiro, John Tavolieri (Loblaws Companies); Anthony Longo (Longo Brothers Fruit Markets); James Petrozzi (M&M Meat Shops); Don Lebovitz (Promotivate International); Ken Keelor and Duncan Reith (Sobeys); Domenic Calce and Paul Del Duca (The Great Atlantic and Pacific Co).

HEEL 'N' WHEEL-A-THON

They are all ages and they come from every walk of life. Participants in the 11th Annual June Heel 'n' Wheel-A-Thon raised another record-breaking \$1.42 million. True to form, the weather was variable across the country during the various events, but warm hearts beat with an enthusiasm that made this another incredibly successful year.

Thanks to M&M Meat Shops, P&G Pharmaceuticals, Imodium, Campbell's, ConAgra Foods, Heinz, Kellogg's and Just 'a Drop for supporting this year's Heel 'n' Wheel-A-Thon.

ALL THAT GLITTERS GALA: MONTREAL

The night air was filled with sounds of music, laughter and gaiety as "A Night in Brazil" danced and dined its way to an outstanding success. The Gala Committee was ecstatic with the \$200,000 raised by their efforts and the support of their enthusiastic guests.

ALL THAT GLITTERS GALA: TORONTO

A lovely fall evening in 2005 was transformed into a "Night in New York". This fun-filled night dazzled over 800 guests, and by the end of the evening, more than \$800,000 was raised for IBD research.

FALL FUNDRAISERS

Across Canada, for our Fall Fundraiser, local chapters of the CCFC organized special fall events of their choice. In 2005, a series of "fun-tastic" events raised an amazing \$195,000 and enhanced awareness about IBD.



FOUNDATION HIGHLIGHTS

YOUTH SUMMIT

In April 2005, the CCFC identified youth as an important priority for the Foundation. An analysis of youth involvement determined that our young volunteers are typically engaged in CCFC activities because of a personal connection with IBD (themselves or a friend/family member).

To further engage our youth and gain their valuable insights into programming and volunteer activities relevant to them, the CCFC organized a Youth Summit in May of 2006. Fifteen young people from across Canada convened for two exciting days, to offer ideas on enhancing youth involvement in fundraising, volunteerism, education and communication.

DIVERSITY PROGRAM

Since 2003, the CCFC has undertaken specific initiatives that recognize and reach out to the diverse multi-cultural communities in Canada. To that end, a number of pilot projects have been held throughout 2004 and 2005 to broaden awareness of IBD and to encourage participation in our fundraising and education efforts. The 2005 programs included:

- Métis Education Program for Mothers (Ke Mama Nnanik) in November 2005 in Calgary

- Abbotsford Education with Dr. Salh for the Punjabi Community in November 2005, Abbotsford
- Education evening with Anushka Nagji, “Life with Crohn’s” at the North East Mosque, September 2005, Calgary

PUBLICATIONS

The Journal is the CCFC’s flagship publication, providing our members with news about Foundation activities and research initiatives. Feature articles focus on the latest news on medical and pharmacological treatments.

Gut Reaction keeps our Professional members informed about the initiatives of the CCFC Research Institute. It focuses on the Institute’s research and education programs, grant deadlines and the work of the Executive Council. It is a key information link between our Professional members and the Foundation.

FOCUS is an electronic publication that inspires our hardworking volunteers. It recognizes the valuable work that they do in raising funds for the Foundation.

CCFC Education Brochures cover a wide variety of topics related to IBD and are available to healthcare professionals and the general public.



LEGACY GRANTS 2006

The Crohn's and Colitis Foundation of Canada Legacy Grant Program is an opportunity to make a leadership gift to inflammatory bowel disease research in the name of an individual, family, organization or corporation. These are the researchers and projects named for 2006.

M&M Meat Shops Grant in Aid of Research (National)
Dr. Wallace MacNaughton – University of Calgary GIA

Fay Shapiro Cutler Grant in Aid of Research (Ontario)
Dr. Alan Lomax – Queen’s University GIA

Colette and Adam Grosvenor Grant in Aid of Research (Quebec)
Dr. Fernand-Pierre Gendron – Université de Sherbrooke GIA

Tammy Truman Summer Student Scholarship (Alberta)
Mr. Phil Bach – University of Alberta

Donna Lee Zampieron (nee Stahls) Summer Student Scholarship (Ontario)
Mr. Simon Houston – Queen’s University

Electronics Industry Hockey Tournament Summer Student Scholarship (Ontario)
Mr. Nikolaus Jewell – McMaster University

Todd White Celebrity Classic Golf Tournament Summer Student Scholarship (Ontario)
Ms. Ariella Zbar – University of British Columbia

The Sorbara Family Summer Student Scholarship (Ontario)
Mr. Michael Peplowski – University of Calgary

2005 Finkelstein Award Winner – Susan Abrametz Summer Student Scholarship (Saskatchewan)
Mr. Travis Murdoch – University of Alberta

FINANCIALS

“The CCFC is committed, first and foremost, to raise increasing funds for medical research”. FROM CCFC VISION STATEMENT

SMALL AND PROUD OF IT!

The CCFC doesn't just talk about devoting money to IBD research – we live it. A small staff of 27 people support the work of 65,000 members, volunteers and supporters across the country. As a result of CCFC's efficient practises, only 8% of the net fundraising proceeds are spent on administration and over 90% is spent directly on research-related activity and education.

The Foundation's financial statements are audited annually. Our financial practises are consistent with the standards of the Canadian Institute of Chartered Accountants. We comply with all government reporting requirements. In addition, our volunteer National Board of Directors monitors our management and programs.


The CCFC is a proud member of the Canadian Marketing Association and subscribes to the Canadian Centre for Philanthropy's Ethical Fundraising and Financial Accountability Code.

FUNDRAISING

CCFC volunteers plan and deliver fundraising programs across Canada. Their formidable energy results in gala dinners, sports tournaments and many other special events, all with the goal of generating monies for medical research.


TOTAL FUNDRAISING PROCEEDS
RAISED IN 2005- 2006: \$7,781,600

Where do the
Proceeds Come From



Donations	26%
Galas and Dinners	23%
Corporate Support	20%
Heel 'n' Wheel-a-Thon	13%
Other	9%
Sports Events	5%
Gaming	4%

How Does the Foundation
Spend the Funds



Research Program	71%
Planned Research	11%
Chapter Services and Education	10%
Administration	8%

WHAT LIES AHEAD GRANTS IN AID OF RESEARCH 2006 – 2009

Emma Allen-Vercoe, University of Calgary *Association of Fusobacterium nucleatum infection with IBD: host and bacterial interactions*

Fernand-Pierre Gendron, Université de Sherbrooke *Modulation of the intestinal epithelial cell Immune responses by the P2Y2 receptor in IBD*

Paul Kubes, University of Calgary *Regulatory T cells and Inflammatory Bowel Disease*

Alan Lomax, Queen's University *Neural regulation of the gastrointestinal microvasculature during colitis*

Wallace MacNaughton, University of Calgary *Inflammation-induced changes in intestinal epithelial aquaporin expression.*

Karen Madsen, University of Alberta *Interactions between bacteria and toll-like receptor 9*

Derek McKay, McMaster University *Inhibition of Colitis by Infection with Parasitic Helminths: Participation of Regulatory T Cells and Macrophages*

John McLeod, Queen's University *Extracellular calcium-sensing receptor stimulates IL-11 secretion which repairs damaged intestinal barrier functions*

Kevin Rioux, University of Calgary *Molecular analysis of the effects of mesalamine on the intestinal microbiota and relevance to anti-inflammatory and cancer chemoprophylactic activity*

Andrew Stadnyk, Dalhousie University *Blocking PMN transepithelial migration controls inflammation*

Theodore Steiner, University of British Columbia *Role of Bacterial Flagellin as an Inflammatory Stimulus in Inflammatory Bowel Disease*

Nathalie Vergnolle, University of Calgary *Involvement of thrombin receptors in mechanisms of colon inflammation*

Pierre-Yves von der Weid, University of Calgary *Role of cyclooxygenase metabolites in inflammation-induced lymph flow alteration in an animal model of IBD*

